BioSpace

Roche cuts muscle-sparing obesity drug after mid-stage disappointment

Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary Chugai Pharmaceutical.

By BioSpace

1 min read
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche cuts muscle-sparing obesity drug after mid-stage disappointment

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights